PROFESSIONAL EDITION

The largest community of pharma leaders

Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business development. Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to….

 

 

 

 

http://www.businesswire.com/news/home/20190523005215/en/Xencor-Appoints-Jeremy-Grunstein-Ph.D.-Vice-President/

Recent Articles